ZSAN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 28, 2020 in the Class Action Filed on Behalf of Zosano Pharma Corporation Limited Shareholders
New York, New York--(Newsfile Corp. - December 17, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Zosano Pharma Corporation (NASDAQ: ZSAN) alleging that the Company violated federal securities laws.
Class Period: February 13, 2017 and September 30, 2020
Lead Plaintiff Deadline: December 28, 2020
Learn more about your recoverable losses in ZSAN:
The filed complaint alleges that Zosano Pharma Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
Shareholders have until December 28, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
For additional information about the ZSAN lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click the link above.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70546